In 2012, Svein Lien, CEO of Biotech Pharmacon (listed on the Oslo Stock Exchange) contacted Percorso Life Sciences to discuss a North American strategy for the company. At the time Biotec was involved in 3 business; wound healing, enzymes as a supplement, and molecular enzymes.
Percorso incorporated the entity in the U.S. in late 2012. In early, 2013 the company asked Dino DiCamillo to develop and lead the commercial molecular enzyme effort on a global basis. Percorso recruited business development managers in the U.S., Europe, and Japan in 2013, managed to negotiate a new OEM contract with Affymetrix (eventually ThermoFisher), oversaw the development and introduction of 4 molecular biology kits. In 2016, Dino led the recruitment of new CEO Jethro Holter, PhD, as Mr. Lien was transitioning out of the company.
Between 2017 and 2019 Dino managed the supplement business that led to an asset sale to Lallemand, divestiture of Biotec BetaGlucans (wound healing business), and a name change to ArcticZymes Technologies ASA.
Percorso’s logistics services helped to facilitate this global growth through bulk import, warehousing, and order fulfillment.
